Role of mucosal-protective agents, rebamipide and polaprezinc, in post-gastric endoscopic submucosal dissection ulcer healing, a randomized controlled study

Role of mucosal-protective agents, rebamipide and polaprezinc, in post-gastric endoscopic submucosal dissection ulcer healing, a randomized controlled study - Role of mucosal-protective agents, rebamipide and polaprezinc, in post-gastric endoscopic submucosal dissection ulcer healing, a randomized controlled study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006233

Enrollment

150

Registered

2011-08-25

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficial gastrointestinal neoplasms

Interventions

PPI PPI plus REB PPI plus PPZ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who undergo gastric ESD.

Exclusion criteria

Exclusion criteria: the patients who undergo additive operation.

Design outcomes

Primary

Measure	Time frame
PPI with mucosal-protective agents, at least in gastric antrum, might contribute to stabilize the efficacy of post-ESD ulcer healing.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026